HOME >> MEDICINE >> NEWS
Adverse Drug Reactions Are Under Reported

(Under reporting of suspected adverse drug reactions to newly marketed ("black triangle") drugs in general practice: observational study)

In this week's BMJ Dr Richard Martin from the Drug Safety Research Unit at Southampton and colleagues from the School of Medicine at the University of Southampton report that general practitioners under-report suspected adverse drug reactions to newly marketed drugs to the Committee on Safety of Medicines. Severe and previously unknown adverse drug reactions to new products are more likely to be reported to the Committee. The authors believe that under-reporting and this bias in reporting needs to be addressed and that doctors should report all adverse reactions, however minor, that their patients have to drugs that have recently been launched onto the market, to enable effective postmarketing surveillance to take place.

Contact:
Dr Richard Martin, Clinical Research Fellow, Drug Safety Research Unit, Southampton


'"/>

Contact: Jill Shepherd
jshepher@bma.org.uk
+44(0)171 383 6529
BMJ-British Medical Journal
10-Jul-1998


Page: 1

Related medicine news :

1. Adverse drug events in nursing homes are far more common than previously identified
2. Adverse events among patients following discharge from hospital
3. More Evidence Of Possible Adverse Effects From New Hormone Use In Women With Heart Disease
4. Scientists To Prepare Advisory Report On Whats Been Learned About The Possible Adverse Health Effects of Electric Fields
5. Beware Of Adverse Drug Reactions
6. Premature Birth Sometimes Can Adversely Affect Infants Ties To Mother
7. New Concepts Proposed To Investigate Drug Reactions
8. Understanding how vulnerabilities may keep women in abusive relationships
9. From town planning to intimate sex: Understanding the risks in our lives
10. Understanding how prostaglandin prevents gut injury during radiation therapy
11. Undertreatment spurs new arrests among drug ofenders diverted under Californias Proposition 36

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Adverse Drug Reactions Are Under Reported

(Date:3/28/2015)... New York (PRWEB) March 28, 2015 ... ) involving devices manufactured by C.R. Bard, Inc. ... underway in U.S. District Court, Southern District of ... Grand, is serving on the Plaintiffs’ Steering Committee. ... the Court has granted certain defendants named in ...
(Date:3/28/2015)... Centurion Service Group will be hosting a live on-site ... their Las Vegas warehouse, located at 4606 Andrews St. Suite ... of equipment from hospitals and surgery centers from around the ... , Buyers will find items of all types including anesthesia, ... said Erik Tivin, CEO of Centurion. , Among the sale’s ...
(Date:3/28/2015)... NV (PRWEB) March 28, 2015 Early ... patients with Type V AC joint injuries, according to ... presented today at the American Orthopaedic Society for Sports ... returned to duty faster when surgery was not performed. ... with 7 receiving surgical treatment and 17 receiving non-surgical ...
(Date:3/28/2015)... March 28, 2015 Healthpointe’s otolaryngologists, medical ... and throat disorders, are now offering a wide ... issue which is characterized by the presence of phantom ... 5 people, tinnitus is a prevalent symptom that can ... it is non-fatal, tinnitus can impede a person’s quality ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 Servpro ... , this week released a report about the link ... of asthma sufferers, and according to recent medical research, ... , According to the Environmental Protection Agency, people with ... reactions. Breathing in mold may trigger asthma attacks for ...
Breaking Medicine News(10 mins):Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 2Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 3Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 4Health News:Medical Equipment Auction to Take Place in North Las Vegas 2Health News:For Type V AC Joint Injuries, Early Surgery May Not Be the Best Approach 2Health News:Healthpointe now Offering Tinnitus Treatments in Clinics throughout Southern California 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 3
(Date:3/27/2015)... Quebec , March 27, 2015  Valeant Pharmaceuticals ... today the closing of its previously announced registered offering ... (the "Offering"). Pursuant to the Offering, the ... $199.00 per share, for aggregate gross proceeds of approximately ... with the U.S. Securities and Exchange Commission a final ...
(Date:3/27/2015)... MARLBOROUGH, Mass. , March 27, 2015 ... ) and privately-held MirImmune LLC, today announced ... license agreement to RXi,s novel and proprietary ... cell-based cancer immunotherapies. The collaboration has the ... and patient friendly cancer treatments that could ...
(Date:3/27/2015)... , March 27, 2015  WebMD Health ... source of health information, today announced an ... National Action Plan for Combating Antibiotic-Resistant ... emphasized the urgency and importance of addressing ... and global health.    The WebMD ...
Breaking Medicine Technology:Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 2Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 4RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 5Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 2Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 3
Cached News: